Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer

NCT03438396 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT03438396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03438396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
Lead sponsor
Seagen Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 12, 2018
Completion date
August 2, 2022
Enrollment
102 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer